Английская Википедия:GW Pharmaceuticals

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Use British English Шаблон:Use dmy dates Шаблон:Infobox company GW Pharmaceuticals Limited[1] is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.[2] Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018.[3] It is a subsidiary of Jazz Pharmaceuticals.

History

GW Pharmaceuticals was founded in 1998 by doctors Geoffrey Guy and Brian Whittle. That year, they obtained a cultivation license from the United Kingdom Home Office and the MHRA, allowing the company to cultivate, possess and supply cannabis to conduct scientific research concerning medical cannabis.[4]

Later in 1998, GW Pharmaceuticals entered into a contract with Hortapharm B.V., a cannabis research and development corporation based in Amsterdam.[5][6]

In 2001, GW Pharmaceuticals listed on the Alternative Investment Market, the junior market of the London Stock Exchange.[7] In May 2013, the company became dual-listed on the NASDAQ and AIM.[8]

In 2014, the company made a deal with New York to develop clinical trials using cannabidiol (CBD) to treat children who suffer from seizures and other medical complications.[9]

In May 2021, Jazz Pharmaceuticals acquired the company.[10][11]

Products

Sativex

Шаблон:Main Nabiximols (trade name Sativex) is a botanical drug that is a cannabis extract, administered as a mouth spray; it was approved in the UK in 2010 as a treatment for multiple sclerosis (MS) patients to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms.[12]

Nabiximols is made with two unknown Cannabis strains, and is extracted with ethanol and carbon dioxide.[13]

In 2020, GW Pharmaceuticals concluded a partnership with Bayer for the distribution of Sativex in the UK.[14] It has an estimated annual production of 100 tons of medicinal cannabis.[15]

Epidiolex

Шаблон:Main In 2015, GW Pharmaceutical initiated Phase 3 clinical trials of cannabidiol oral solution for treatment of two rare disease in children – Dravet syndrome and Lennox–Gastaut syndrome.[16] In August 2015, GW received FDA Fast Track Development Program designation from the US Food and Drug Administration for use of the drug candidate to treat newborns with epilepsy.[17]

The drug, under the brand name Epidiolex, was given US Food and Drug Administration approval in June 2018.[18][19] It was subsequently given European EMA approval in September 2019 under the brand name Epidyolex.[20][21]

See also

Шаблон:Portal

References

Шаблон:Reflist

External links

Шаблон:Cannabis in the United Kingdom Шаблон:Pharmaceutical industry in the United Kingdom Шаблон:Science and technology in the United Kingdom Шаблон:Authority control